Integrated Approaches for Liver Fibrosis Treatment are anticipated to open up new avenue for Liver Fibrosis Treatment Market
Liver Fibrosis
Treatment Market
Market
Overview:
Liver fibrosis is characterized by excessive accumulation of extracellular
matrix proteins in the liver which disrupts the normal liver architecture and
function. Key causes of liver fibrosis include chronic hepatitis B and C virus
infections, excessive alcohol consumption and non-alcoholic steatohepatitis
(NASH). The current treatment landscape includes antiviral drugs,
corticosteroids and immunosuppressive agents. However, there is an urgent need
for effective anti-fibrotic therapies to halt or reverse the fibrosis process.
Market Dynamics:
Two key drivers of the liver fibrosis treatment market are growing prevalence
of chronic liver diseases and large therapeutic opportunity. Chronic hepatitis
B and C affect nearly 300 million people globally and are leading risk factors
for liver fibrosis. In addition, the global burden of NASH is rising rapidly
due to the obesity and diabetes pandemic. Effective anti-fibrotic drugs can
halt disease progression and reduce the need for costly late-stage treatments
like liver transplantation. Several candidates are in the pipeline targeting
key molecular pathways involved in fibrosis development. For example,
galectin-3 inhibitors reduce fibrogenesis by blocking galectin-3 mediated
collagen deposition. Successful approvals will drive significant market growth
in the forecast period.
The
global Liver
Fibrosis Treatment Market Size is estimated to be valued at US$ 16.29 Bn in 2023 and is expected to
exhibit a CAGR of 10.8 % over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Segment Analysis
The global liver fibrosis treatment market is segmented into Imaging
techniques, anti-fibrotic drugs, immunomodulators, liver transplantation and
others. The anti-fibrotic drugs segment dominates the market and accounts for
the largest revenue share. This is mainly because anti-fibrotic drugs such as
monoclonal antibodies, proteasome inhibitors and interferons are highly
prescribed by physicians as first line therapies to treat liver fibrosis.
PEST Analysis
Political: The government across various countries are steadily increasing
healthcare expenditure to curb the growing burden of liver diseases. This is
positively impacting the growth of the liver fibrosis treatment market.
Economic: The rising per capita income levels have increased healthcare
spending capacity among individuals globally. This provides a conducive
environment for market growth.
Social: Growing awareness about lifestyle-related liver disorders and available
treatment options through various health programs is driving more patients to
seek diagnosis and treatment.
Technological: Advancements in imaging technologies help detect fibrosis at an
early stage. Development of novel anti-fibrotic drugs with higher efficacy and
improved tolerability is further fueling the market expansion.
Key Takeaways
The global liver fibrosis treatment market is expected to witness high growth,
exhibiting CAGR of 10% over the forecast period, due to increasing prevalence
of chronic liver diseases such as hepatitis, non-alcoholic fatty liver disease
and others. The market size for 2023 is estimated at US$ 16.29 Bn.
Regional analysis shows that North America commands the largest share in the
global market owing to growing obesity rates and availability of advanced
treatment options. Europe also captures a significant share and is projecting
lucrative growth prospects supported by rising alcoholic liver disease
incidence and strong healthcare infrastructure.
Key players operating in the liver fibrosis treatment market are Gilead
Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and
Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc.,
FibroGen, Inc., and Pharmaxis Limited. These companies are focusing on
developing novel treatment approaches through extensive R&D initiatives and
clinical trials to gain higher market share.
For
more details on the report, Read-
https://www.pressreleasebulletin.com/liver-fibrosis-treatment-market-size-and-share/
Comments
Post a Comment